APA (7th ed.) Citation

Friedman, S. M., Xu, Y., Sherman, S., Kuznik, A., Mojebi, A., Keeping, S., . . . Patel, N. (2025). Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. Ophthalmology & Therapy, 14(11), 2919. https://doi.org/10.1007/s40123-025-01247-3

Chicago Style (17th ed.) Citation

Friedman, Scott M., Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, and Nimesh Patel. "Aflibercept 8 Mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials." Ophthalmology & Therapy 14, no. 11 (2025): 2919. https://doi.org/10.1007/s40123-025-01247-3.

MLA (9th ed.) Citation

Friedman, Scott M., et al. "Aflibercept 8 Mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials." Ophthalmology & Therapy, vol. 14, no. 11, 2025, p. 2919, https://doi.org/10.1007/s40123-025-01247-3.